Viewing data from:

CLEMASTINE FUMARATE

ANDA

CLEMASTINE FUMARATE | A073095 | TEVA PHARMACEUTICALS USA

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Clemastine Fumarate (2023)

Total Spending

$21.3M

Total Claims

5,624

Beneficiaries

1,746

Avg Cost/Unit

$8.87

Spending Trend

$297K(2019)→$200K(2020)→$1.6M(2021)→$24.7M(2022)→$21.3M(2023)

YoY Change:-15.3%

5yr CAGR:+76.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — EQ 0.5MG BASE/5ML

0 patents0 exclusivities▴

SYRUP;ORAL | Approved: Apr 21, 1992

No patent or exclusivity listings for this strength.